Psychopharmacological treatment in borderline personality disorder

Authors

  • M. Díaz-Marsá Hospital Clínico San Carlos Madrid (Spain)
  • S. González Bardanca Servicio de Psiquiatría Complejo Universitario Hospitalario Juan Canalejo Martímo de Oza La Coruña (Spain)
  • K. Tajima Hospital Clínico San Carlos Madrid (Spain)
  • J. García-Albea Hospital Clínico San Carlos Madrid (Spain)
  • M. Navas Hospital Clínico San Carlos Madrid (Spain)
  • J. L. Carrasco Hospital Clínico San Carlos Madrid (Spain)

Keywords:

Borderline personality disorder, Treatment, Affective instability, Impulsivity, Aggressivity, Anxiety, Cognitive-perceptive disfunction

Abstract

Borderline personality disorder is a disorder with important social and clinical repercussions, which has been treated mainly by psychotherapy. In recent years, the syndromic analysis of this disorder has allowed us to identify different symptoms capable of being improved with psychopharmacology treatment. Thus, its complex symptomatology could be included in four clinical dimensions: impulsive-aggressive, affective instability, cognitive-perceptive and anxiety-inhibition. Antidepressants, mood stabilizers, antipsychotics, anxiolytics, or more recently omega-3 fatty acids have shown efficacy in the treatment of symptomatic dimensions of this disease.

We have reviewed scientific articles (reviews, clinical trials or clinical guidelines) published over the last ten years and have proposed therapeutic algorithms for psychopharmacology management in these patients.

 

Published

2008-01-01

How to Cite

Díaz-Marsá, M., et al. “Psychopharmacological Treatment in Borderline Personality Disorder”. Actas Españolas De Psiquiatría, vol. 36, no. 1, Jan. 2008, pp. 39-49, https://actaspsiquiatria.es/index.php/actas/article/view/234.

Issue

Section

Review